-
A federal advisory panel will meet to decide who will get the swine flu vaccine when there isn"t enough for everyone. Pregnant women, who account for six percent of US swine flu deaths since the pandemic began in April, may follow healthcare workers who are at the top of the list. According to Dr. Denise Jamieson, an epidemiologist with the CDC, the notion that the flu only affects pregnant women
제약단신
메디칼라이터팀
2009.07.30 00:00
-
The FDA has warned consumers against using body-building products that are sold as nutritional supplements because they may contain steroids or steroidlike substances. The FDA is not certain about how many products its warning affects but consumers should be wary of body-building products claiming to enhance or diminish the effects of hormones like testosterone, estrogen or progestin. FDA investig
제약단신
메디칼라이터팀
2009.07.30 00:00
-
The US government has stopped a study of a drug for sickle cell disease sufferers a year early because of an increase in serious side effects. The drug Revatio [sildenafil] is approved for general pulmonary hypertension which is a type of lung damage that is the leading killer of sickle cell patients. The drug is not approved for use in sickle cell patients because doctors did not know how they wo
제약단신
메디칼라이터팀
2009.07.30 00:00
-
President Gloria Macapagal Arroyo has signed an executive order that will impose price controls on medicines made from five compounds. The order will cover Pfizer"s Norvasc (amlodipine besylate), the antibiotic azithromycin, cholesterol-lowering ator-vastatin and two cancer treatments- doxorubicin and cytarabin. Pharmaceutical companies have voluntarily agreed to price reductions of 50 percent on
제약단신
메디칼라이터팀
2009.07.30 00:00
-
According to Gary J. Buehler, director of the office of generic drugs in the Food and Drug Administrations" Center for Drug Evaluation and Research, through rigorous quality and safety testing it is shown that generics are of identical strength, purity and quality as the original brand-name drug. This report comes as patients often cite their own experiences as proof that generics are inferior es
제약단신
메디칼라이터팀
2009.07.29 00:00
-
Researchers from Harvard Medical School followed 1,441 patients from three studies and found that rates of vision loss, kidney damage, and heart disease were cut in type 1 diabetics if long-term, intensive insulin therapy was maintained. The study published in the Archives of Internal Medicine compared patients having three shots per day with those having between one and two shots. It was found th
제약단신
메디칼라이터팀
2009.07.29 00:00
-
The Sanofi-Pasteur vaccines arm will gain a majority stake in Hyderabad-based Shantha Biotechnics by buying ShanH, a subsidiary of French healthcare-products group Merieux Alliance. The deal, expected to close by the end of the third quarter, will assist Sanofi"s expansion into India as well as being able to access Shantha"s new product pipeline including an experimental typhoid vaccine.
제약단신
메디칼라이터팀
2009.07.29 00:00
-
Amgen, the US biotechnology group hopes to expand sales in fast-growing middle income markets as it announces a partnership with GlaxoSmithKline. Glaxo will market denosumab for both osteoporosis and cancer treatment in emerging markets including Brazil, China, India and South Korea. The drug will be marketed jointly in Europe and Glaxo will pay $120 million initially to share in the profits. Deno
제약단신
메디칼라이터팀
2009.07.29 00:00
-
The European Medicines Agency,has expressed negative opinion on the use of Erbitux in non-small-cell lung cancer, saying benefits of using the drug to treat the disease didn"t outweigh its risks. This comes as Merck KGaA wishes to extend the use of Erbitux which is currently approved to treat certain types of bowel, head and neck cancer.
제약단신
메디칼라이터팀
2009.07.28 00:00
-
In lawsuits over Wyeth’s hormone therapy drugs Prempro [conjugated estrogens/medroxyprogesterone acetate] and Premarin [conjugated estrogens], federal judges have ordered that documents pertaining to Wyeth’s ghostwriting practices be unsealed. The plaintiffs maintain that in hiring professional writing companies and getting them signed off by doctors and then getting them published, Wyeth was abl
제약단신
메디칼라이터팀
2009.07.28 00:00
-
In a study at the University of Rochester Medical Center it was found that tamoxifen kills yeast in mice with Candida infections causing the fungus to break down before the disease develops. The infection is known to be fatal in patients with depressed immune systems including patients with cancer, HIV and those taking immunosuppressants for chronic conditions.
제약단신
메디칼라이터팀
2009.07.28 00:00
-
The World Health Authority"s Assistant Director-General for Health Security and Environment has said that there must be no doubt in swine flu vaccine safety prior to it being given to the public. According to Fukuda it is still early in the pandemic and the disease is likely to spread for sometime.
제약단신
메디칼라이터팀
2009.07.28 00:00
-
The EU"s top drug regulators will fast-track approval for the swine flu vaccine. Countries such as Britain, Greece, France and Sweden may begin using it within weeks so people can be vaccinated before winter. Dr. Keiji Fukuda, the WHO"s flu chief is concerned about potential dangers whereas Leonard Marcus, Harvard University public health expert said not having a vaccine if the virus gets worse
제약단신
메디칼라이터팀
2009.07.28 00:00
-
Forteo [teriparatide], Eli Lilly and Co"s osteoporosis medication has been approved by the Food and Drug Administration for use in inflammatory conditions like rhematoid arthritis and obstructive pulmonary disease where patients are taking glucocorticoids. Sustained use of glucocorticoids causes bone fractures in half of patients using them. The company submitted data showing that the drug increa
제약단신
메디칼라이터팀
2009.07.25 00:00
-
Merck KGaA has submitted a marketing authorization application for the pill, cladribine for multiple sclerosis to the European Medicines Agency and plans an application to US regulators this quarter. Merck presented clinical trial data at the American Academy of Neurology conference. The data from a two-year trialshowed that the drug halved the risk of relapse and some patients developed a low whi
제약단신
메디칼라이터팀
2009.07.25 00:00
-
According to Roche sales of Tamiflu[oseltamivir phosphate] tripled to 1 billion Swiss francs ($931 million) since the outbreak of swine flu in April spurred by retail sales and the stockpiling of the drug by governments and corporations. Roche plans to produce 400 million packs annually by start of 2010 a huge increase given that for the last five years it has only produced 300 million packs in to
제약단신
메디칼라이터팀
2009.07.24 00:00
-
Bristol-Myers Squibb"s acquisition of biotech firm Medarex will give it full rights to Ipilimumab, Medarex"s lead drug which is in final-stage trial for advanced melanoma. The drug works by enabling the immune system to kill cancer cells but many of these treatments have failed as sometimes the cancer finds a way to fight back. Bristol-Myers move is seen as risky but it hopes to get better resul
제약단신
메디칼라이터팀
2009.07.24 00:00
-
Bristol-Myers Squibb Co. agreed to pay $125 million to settle a shareholder suit regarding the generic version of Plavix [clopidogrel bisulfate]. In the settlement, Apotex was permitted to make the drug and Bristol-Myers agreed to relinquish certain legal rights and entered into oral agreements with Apotex. Bristol-Myers said that it would not undercut Apotex if it delayed releasing the generic in
제약단신
메디칼라이터팀
2009.07.24 00:00
-
A study appearing online in the New England Journal of Medicine involving 3,070 adults treated with peginterferon alfa-2b (Pegintron) plus ribavirin, or peginterferon alfa-2a (Pegasys) plus ribavirin, shows that both were effective and safe in the treatment of Hepatitis C and worked in 39.8 and 40.9 percent of patients, respectively.
제약단신
메디칼라이터팀
2009.07.24 00:00
-
According to research presented at the International AIDS Society conference, Merck & Co."s Isentress [raltegravir] failed to reduce low-level reservoirs of HIV. A study was done on patients whose viral levels were almost undetectable for 6 months while using standard antivirals. Participants had a 12 week course of Isentress or placebo then a further 12 week course of an alternate therapy. No di
제약단신
메디칼라이터팀
2009.07.24 00:00